AEON Biopharma, Inc.

AEON · NYSE AMERICAN

AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.

Follow Add to Watchlist Ask Question

NYSE AMERICAN AEON Coverage Bootstrap Biotechnology Biosimilars Therapeutic Neurotoxin

Latest ReportMay 14, 2026AEON Biopharma: the BOTOX biosimilar bet running on a Q3 cash runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

AEONBiosimilars

Clear tags

MatchAny tag All tags

Latest Thesis

AEON Biopharma: the BOTOX biosimilar bet running on a Q3 cash runway

May 14, 2026Research reportSlides available

Read report Open slides Discussion (0)

AEON Biopharma, Inc.Biopharma: the BOTOX biosimilar bet running on a Q3 cash runwayMay 14, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

AEON Biopharma: the BOTOX biosimilar bet running on a Q3 cash runwayAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.NYSE AMERICANMay 14, 2026Research reportRead Slides